1. Home
  2. PRZO vs POAI Comparison

PRZO vs POAI Comparison

Compare PRZO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$1.24

Market Cap

25.1M

Sector

N/A

ML Signal

HOLD

Logo Predictive Oncology Inc.

POAI

Predictive Oncology Inc.

HOLD

Current Price

$5.95

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
POAI
Founded
2014
2002
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
6.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
PRZO
POAI
Price
$1.24
$5.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
456.9K
42.7K
Earning Date
08-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,007,440.00
$1,664,407.00
Revenue This Year
N/A
$486.27
Revenue Next Year
N/A
$65.50
P/E Ratio
N/A
N/A
Revenue Growth
80.42
320.71
52 Week Low
$0.53
$3.88
52 Week High
$3.16
$45.90

Technical Indicators

Market Signals
Indicator
PRZO
POAI
Relative Strength Index (RSI) 41.65 47.30
Support Level $1.25 $3.88
Resistance Level $1.51 $6.25
Average True Range (ATR) 0.07 0.76
MACD -0.01 0.11
Stochastic Oscillator 6.90 79.01

Price Performance

Historical Comparison
PRZO
POAI

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Share on Social Networks: